COVID-19: State of the Vaccination

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World He...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenton, Caroline, Lamb, Yvette N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Practical Issues and Updates
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517556/
https://www.ncbi.nlm.nih.gov/pubmed/34667427
http://dx.doi.org/10.1007/s40267-021-00869-4
Descripción
Sumario:The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.

Ejemplares similares